What happens when a drug comes off the FDA shortage list?

What actually changes?

Two different things, depending on which pathway the preparation was travelling.

FDA states the outsourcing-facility rule in its own words: a facility registered under section 503B "may not compound a drug product that includes a bulk drug substance unless: the bulk drug substance appears on a list identifying bulk drug substances for which there is a clinical need (the 503B bulks list), or the drug product compounded from such bulk drug substance appears on FDA's drug shortage list at the time of compounding, distribution and dispensing."

There are only two gateways, and shortage is one of them. When the shortage ends and the substance is not on the 503B bulks list, that route closes entirely.

For a state-licensed 503A pharmacy the effect is narrower but real. FDA's position is that "a drug is not considered to be commercially available if it is on FDA's drug shortages list and limitations on compounding essentially copies are not applicable in these circumstances." Substance eligibility never depended on the shortage where it rested on the substance being a component of an approved drug — what changes is that the restriction on compounding an essential copy switches back on.

Is there a wind-down period?

Yes, and it is a standing rule rather than a one-off concession.

FDA has said it "may take action if an outsourcing facility continues to fill new orders after the approved drug is removed from FDA's drug shortage list, or if it continues to fill existing orders more than 60 days after the drug has been removed."

Read the two halves separately. New orders are exposed immediately on removal; existing orders have a sixty-day tail. This is distinct from the substance-specific enforcement-discretion windows FDA announced when particular shortages resolved, which were separate announcements with their own dates.

What does the test for "essentially a copy" look like?

Same active ingredient, same or easily substitutable strength, same route — unless the prescriber documents a patient-specific difference.

FDA's restatement: the compounded product "has the same active pharmaceutical ingredient(s) (API) as the commercially available drug product in the same, similar or an easily substitutable strength," and the commercially available product "can be used by the same route of administration … prescribed for the compounded drug product. This is unless a prescriber determines and documents the compounded drug product contains a change that produces a significant difference from the commercially available drug product for an identified individual patient."

FDA has separately said it does not intend to act against a compounder for compounding an essential copy regularly or in inordinate amounts "if the compounder fills four or fewer prescriptions of that compounded drug product during a calendar month." The doctrine itself is explained at essentially a copy of a commercially available drug.

Does adding a second ingredient avoid the copy rule?

No — and FDA chose that exact configuration as its illustration of the problem, which is why the claim is worth checking carefully when a supplier makes it.

FDA has published a worked example: it "may consider a compounded drug product that combines semaglutide API and another API, such as vitamin B12 (cyanocobalamin), to be essentially a copy" where the strengths of each sit within ten per cent of the respective commercially available products and the route of administration is the same.

Read that carefully, because it is frequently cited backwards. The combination FDA named is not a safe harbour it carved out; it is the example it gave of a product that is essentially a copy. A supplier presenting a second ingredient as a compliance feature, a personalisation, or the reason a preparation is permissible is contradicted by FDA's own illustration. The only route the rule itself provides is the prescriber's documented, patient-specific determination of a significant difference.

What has this looked like in practice?

Two resolutions, each followed by a dated discretion window and litigation.

The pattern to take from this: a sixty-day 503A window and a ninety-day 503B window from the resolution decision, with the actual end dates landing later because FDA tied them to the court rulings. FDA's flat current statement on those two substances is that they "do not currently appear on the 503B bulks list or on FDA's drug shortage list."

Is anything currently on the list?

Yes — one of the three substances in that proposal is in a different position from the other two, and it must not be described alongside them.

As of a live database pull on 2026-08-28, liraglutide injection carried "Current" shortage records across multiple manufacturers' presentations, with individual records updated as recently as 2026-08-27 and reasons including delay in shipping and discontinuation of manufacture. While it remains listed, the shortage gateway is open for an outsourcing facility, and the essentially-a-copy restriction does not apply to it in the way it applies to a resolved substance.

Three cautions come with that. Status is recorded per presentation, not per substance, so a single answer for "liraglutide" flattens a table. The 503B condition requires listing "at the time of compounding, distribution and dispensing," so the relevant date is the transaction date rather than the date you read a page. And a proposal to exclude a substance from the bulks list would not close the shortage route while the shortage lasts, because the two gateways are independent.

We maintain a dated view of substance status at the compounding status tracker.

Why is the bulks list a separate question?

Because it is the other gateway, it works differently, and the two are constantly conflated.

The 503A and 503B bulks lists are statutory lists created by rulemaking. Both are short, both are largely confined to topical substances, and neither contains a peptide. A substance on one is eligible regardless of shortage status; a substance on neither has no bulks route whatever the shortage position.

Are the interim categories the same as the bulks lists?

No, and this is the most misread distinction in the subject.

FDA's own description of Category 1 is that it "does not intend to take action against a compounder for compounding drugs using bulk drug substances listed in category 1, provided that the conditions described in the guidance document are met." That is enforcement discretion, not listing and not approval. It is withdrawable, and FDA has said it will not place substances nominated on or after 7 January 2025 into these categories at all, so there is no longer a route in.

Two further cautions. A 503A category tells you nothing about the 503B answer — the two category lists disagree, sometimes on the same substance split by route. And the false claim that a substance "moved to Category 1" and is therefore permitted fails on each half separately: a category placement is not a move onto either bulks list, and a placement that does exist confers enforcement discretion rather than permission. Correcting only one half leaves the other standing.

What should a buyer take from all this?

That the correct question is dated and per substance, and that a supplier's confidence is not evidence.

If a supplier tells you a preparation is available on a shortage rationale, the checkable version of that claim names the substance, names the presentation, and states the date the shortage list was consulted. If it tells you a substance "is on the list" without a date, it has told you what was true at some point.

And a federal answer is not a state answer. Whether you may hold any of this as office stock is decided by your own state's rules, at office-use compounding by state, and by the patient-specific requirement at what is a valid prescription for a compounded medication. Which pathway currently applies to a given substance, each row dated to the day its FDA source was read, is at the compounding status tracker.

To have a preparation's current pathway checked against your state before you rely on it, you can apply for an account.